Biotechnology ETFs have leapt out of the gate in 2015 with another strong spurt of momentum that has catapulted them to the top of sector rankings. The unequivocal asset leader in this category is the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB), which has more than $8 billion under management.
IBB has gained more than 12 percent so far this year and continues to shine as an industry-leading benchmark. This performance, while impressive, is still a far cry from several specialized biotech ETFs with unique index construction methodologies.
ALPS Medical Breakthroughs
The relatively new ALPS Medical Breakthroughs ETF (NYSE: SBIO) was released on the last day of 2014 and has achieved an impressive return ...
/www.benzinga.com/general/biotech/15/02/5274798/the-best-biotech-etf-isnt-always-the-biggest alt=The Best Biotech ETF Isn't Always The Biggest>Full story available on Benzinga.com
More...